Small Cell Lung Cancer (SCLC)

Latest News

Factors including age, gender, and facility type may influence the likelihood of pain referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.
Demographic Factors May Impact Pain Management Referrals in SCLC/NSCLC

March 15th 2023

Factors including age, gender, and facility type may influence the likelihood of pain specialist referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.

Investigators indicate that strategies are necessary to identify patients with extensive-stage small cell lung cancer who won’t benefit from immunotherapy-based treatment.
IO/Chemo Associated With Higher Toxicity Risk in ES-SCLC

March 14th 2023

A favorable Glasgow prognostic score appears to correlate with improved overall survival and progression-free survival following treatment with atezolizumab plus carboplatin and etoposide for small cell lung cancer.
Glasgow Prognostic Score May Predict Atezolizumab/Chemo Outcomes in SCLC

February 22nd 2023

Patients 70 years or older with limited stage small cell lung cancer appear to tolerate concurrent thoracic chemoradiotherapy and have similar disease control rates as younger patients.
Concurrent CRT Garners Disease Control, Safety in SCLC Regardless of Age

February 13th 2023

Findings from the phase 1/2 CA001-030 study indicate that BMS-986012 in combination with nivolumab is well tolerated among patients with small cell lung cancer.
BMS-986012 ± Nivolumab Appears Well-Tolerated in Relapsed/Refractory SCLC

January 17th 2023

Video Interviews
Podcasts
In the final part of the small cell lung cancer podcast series, CancerNetwork® and Wade Iams, MD, discuss the future of treating patients with this disease.
In episode 3 of a 4-part small cell lung cancer podcast series, Wade Iams, MD, highlights practical considerations for treating patients with small cell lung cancer, including managing toxicities and the impact of treatment on a patient’s quality of life.
Wade Iams, MD, broke down some of the different treatment options, including lurbinectedin and topotecan, for patients with relapsed/refractory small cell lung cancer in the second episode of a 4-part small cell lung cancer podcast series.
In the first episode of a 4-part series, CancerNetwork® spoke with Wade Iams, MD, about the various first-line treat options that are available for patients with small cell lung cancer.
Latest CME Events & Activities

Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers

View More

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®

View More

Trekking Through the Latest Updates for ROS1-Targeted Therapies

View More

Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care

View More

Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC

View More

Navigating the Latest Data on NTRK-Targeted Therapies

View More

Community Practice Connections™: 17th Annual New York Lung Cancers Symposium

View More

Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow

View More

Show Me Your Care Plan™: Monitoring and Managing Patients With EGFR Exon20 Insertion+ NSCLC

View More

Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care

View More

Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers

View More

Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care

View More

Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC

View More

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

View More

Medical Crossfire: How Should We Leverage Multidisciplinary Lung Cancer Care Teams in Managing Earlier Forms of NSCLC... When the Goal Is Cure?

View More

Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC

View More

Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC

View More

Expert Illustrations & Commentaries™: Exploring the Clinical Rationale for Antagonizing Inflammatory IL-1-beta Signaling in NSCLC

View More

Onco-Nurse Academy™: Exploring an Advent of Targeted Therapies Across Advanced NSCLC Care and Strategies for Managing Adverse Events Associated With Treatment

View More

Patient, Provider, and Caregiver Connection™: Shedding a Light on the Patient Journey with KRAS Mutated Lung Cancer

View More

Clinical Vignettes®: Multidisciplinary Discussions on the Application of Novel EGFR Exon 20 Targeted Regimens for NSCLC Management

View More

Expert Illustrations & Commentaries™: Exploring the Role of Novel Antibody-Drug Conjugates in Advanced NSCLC

View More

Advances In™ NSCLC: Exploring CEACAM5 As A New Therapeutic Target

View More

Community Practice Connections™: Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!

View More

Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care

View More

Advances In™: The Role of NRG1 Fusions Across Tumor Types

View More

Medical Crossfire®: Leveraging EGFR Mutation Profiles to Personalize Therapeutic Decisions in Resected and Metastatic NSCLC Settings

View More

Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future

View More

Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!

View More

More News